Monotherapy CRB-701 data at ASCO 2026 (late May/early June) and CANYON-1 obesity data in summer 2026 are key catalysts. The slight EPS miss is negligible; focus on pipeline execution.
Price Chart
Executive Summary
Corbus reported Q1 2026 net loss of $23.0M ($1.23/share), slightly missing consensus EPS of -$1.22. The company highlighted FDA alignment on CRB-701 registrational path for HNSCC and cervical cancer, completed enrollment in the CANYON-1 obesity study with data expected summer 2026. Cash of $138.2M expected to fund operations into 2028.
Key Financial Metrics
Key Facts
- Q1 2026 net loss $23.0M vs $17.0M a year ago
- EPS -$1.23 (consensus -$1.22, 2.5% miss)
- Cash and investments $138.2M at March 31, 2026
- FDA alignment achieved for CRB-701 registrational study in 2L HNSCC
- CANYON-1 Phase 1b obesity study fully enrolled (n=240), topline data expected summer 2026
Financial Impact
Net loss per share -$1.23 vs consensus -$1.22; operating expenses increased $4.5M YoY to $24.3M
Risk Factors
- Clinical trial failure risk for CRB-701 or CRB-913
- Dilution risk with $138M cash runway into 2028 but no revenue
- Competition in Nectin-4 ADC and obesity spaces
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3292746 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 12d ago | 8-K | $4.33 | awaiting T+60 | — | $4.15 (−4.16%) |
Sep 30, 2026 27d ago | SC 13G | $6.34 | awaiting T+60 | — | $4.15 (−34.54%) |
Sep 22, 2026 5w ago | Institutional Cluster | $7.88 | awaiting T+60 | — | $4.15 (−47.30%) |
Sep 14, 2026 6w ago | 8-K | $8.08 | awaiting T+60 | — | $4.15 (−48.64%) |
Sep 11, 2026 6w ago | Press Release | $8.08 | awaiting T+60 | — | $4.15 (−48.64%) |
Aug 12, 2026 10w ago | Insider Cluster | $10.08 | awaiting T+60 | — | $4.15 (−58.83%) |
Aug 10, 2026 11w ago | Insider Cluster | $9.51 | awaiting T+60 | — | $4.15 (−56.36%) |
May 26, 2026 22w ago | 8-K | $7.91 $9.99 | ▲ +26.30% | ▲ +23.57% | $4.15 (−47.53%) |
May 21, 2026 22w ago | 8-K | $11.51 $10.49 | ▼ −8.86% | ▼ −13.16% | $4.15 (−63.94%) |
May 14, 2026 23w ago | 8-K | $11.98 $9.46 | ▼ −21.04% | ▼ −24.62% | $4.15 (−65.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers